Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Chemomab Therapeutics Ltd. (ANCN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
8-K
| Quarterly results |
| 01/11/2023 |
8-K
| Quarterly results |
| 01/03/2023 |
8-K
| Quarterly results |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 06/08/2022 |
8-K
| Quarterly results |
| 06/01/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/09/2022 |
8-K
| Quarterly results |
| 02/11/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 12/16/2021 |
8-K
| Quarterly results |
| 12/03/2021 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/08/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"TEL AVIV, Israel, November 8, 2021 -- Chemomab Therapeutics Ltd. , a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that Donald R. Marvin has been named Chief Financial Officer, Executive Vice President and Chief Operating Officer. Mr. Marvin is a seasoned biotechnology executive with over 35 years of experience at growth enterprises in corporate finance and fundraising, strategy, corporate development, mergers and acquisitions, and operations. “Don’s deep expertise in building life sciences companies through a combination of organic growth and targeted strategic acquisitions will be invaluable as we advance our promising clinical programs and leverage the scient..." |
|
| 11/03/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/26/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 10/25/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/02/2021 |
8-K
| Quarterly results |
| 08/13/2021 |
8-K
| Quarterly results |
| 07/22/2021 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/13/2021 |
8-K
| Quarterly results |
| 04/05/2021 |
8-K
| Other Events, Financial Statements and Exhibits |
| 03/16/2021 |
8-K
| Quarterly results |
| 03/09/2021 |
8-K
| Quarterly results |
| 02/08/2021 |
8-K
| Other Events |
| 12/15/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Agreement and Plan of Merger, by and among Anchiano Therapeutics Ltd., Chemomab Ltd. and CMB Acquisition Ltd.",
"Form of Company Shareholder Support Agreement, by and between Chemomab Ltd. and each of the parties named in each agreement thereof",
"Form of Chemomab Shareholder Support Agreement, by and between Anchiano Therapeutics Ltd. and each of the parties named in each agreement thereof",
"Form of Lock-Up Agreement, by each of the parties named in each agreement thereof",
"Chemomab Warrant, by and among Anchiano Therapeutics Ltd. and the shareholders of Chemomab",
"Cashless Exercise Notice, Amendment, Waiver, Release and Termination, by and among Anchiano Therapeutics Ltd., Shavit Capital Fund III (US), L.P., Shavit Capital Fund IV (US), L.P., Shavit Capital Fund 3 (Israel), L.P., Shavit Capital Fund 4 (Israel), L.P., Clal Biotechnology Industries Ltd. and other investors",
"Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement" |
|
| 10/20/2020 |
8-K
| Quarterly results |
| 07/15/2020 |
8-K
| Quarterly results |
| 07/09/2020 |
8-K
| Quarterly results |
| 05/21/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|